Debiopharm International SA
Debiopharm International SA
Debiopharm International Sa | Date: 2015-03-31
Fusion polypeptides have an FGFR2 polypeptide and cDNAs encode such fusion polypeptides. Methods of diagnosing the presence of the fusion polypeptides or of a gene or RNA sequence coding therefore in a sample from a subject as well as methods of treatment of a tumor instructed by the latter diagnosis.
Debiopharm International S.A. | Date: 2015-06-01
device for separating and concentrating target particles or molecules from a fibrinogen containing sample of liquid comprises a container (1) for collecting the sample and a closure (2). The container (1) comprises a first end and a second end and at least one interior wall defining a reservoir portion (5) for receiving the sample. The reservoir portion (5) comprises at least one anchor element (4) to locally catch a polymerized fibrin pellet formed upon the addition of the sample into the container. The separation and concentration process is operated by trapping the target particles or molecules into the so-formed polymerized fibrin pellet that are captured on the anchor element (4).
News Article | May 23, 2017
LAUSANNE, Switzerland & WALTHAM, Mass.--(BUSINESS WIRE)--Debiopharm International SA (Debiopharm – www.debiopharm.com), part of Debiopharm Group™, a Switzerland-based biopharmaceutical company, and ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Debiopharm has acquired ImmunoGen’s IMGN529/DEBIO 1562, a clinical-stage anti-CD37 ADC for the treatment of patients with B-cell malignancies, such as non-Hodgkin lymphomas (NHL). Under the terms of the agreement, ImmunoGen received a $25 million upfront payment for IMGN529/DEBIO 1562 and is entitled to a $5 million milestone payment to be paid after completion of the transfer of ImmunoGen technologies related to the asset, which the parties expect to achieve by the end of 2017. In addition, ImmunoGen is eligible for a second success-based milestone payment of $25 million upon IMGN529/DEBIO 1562 entering a Phase 3 clinical trial. “The purchase of IMGN529/DEBIO 1562 from a pioneer in the field of ADCs represents a strategic investment leveraging our expertise and track record in Oncology and supports our strong commitment to deliver targeted therapies and precision medicines to help patients suffering from severe diseases,” stated Bertrand Ducrey, CEO of Debiopharm. “IMGN529/DEBIO 1562 has already generated compelling clinical data and we look forward to further exploring it in combination with Rituxan®, which could provide an attractive alternative to conventional chemotherapies for patients with NHL such as diffuse large-cell B-cell lymphoma (DLBCL),” said Chris Freitag, vice president of clinical research and development of Debiopharm. IMGN529/DEBIO 1562 demonstrated evidence of anticancer activity in NHL in a Phase 1 monotherapy trial and successfully completed a safety run-in study in combination with Rituxan®. The product is now ready to move forward into a Phase 2 trial in NHL, and particularly in DLBCL for which it has Orphan Drug status. “With a strong history of developing and bringing oncology drugs to market, Debiopharm offers the right mix of resources and capabilities to advance IMGN529/DEBIO 1562 through its next phase of development,” stated Mark Enyedy, president and chief executive officer of ImmunoGen. “Consistent with the strategic review of our portfolio undertaken last fall, this transaction further enables us to prioritize our development efforts on mirvetuximab soravtansine and our IGN programs, while generating near-term value from IMGN529/DEBIO 1562.” About Debiopharm International SA Part of Debiopharm Group™ – a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management – Debiopharm International SA focuses on developing prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide. For more information, please see www.debiopharm.com We are on Twitter. Follow @DebiopharmNews at http://twitter.com/DebiopharmNews About ImmunoGen, Inc. ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®, in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com. Kadcyla® and Rituxan® are the registered trademarks of their respective owners. This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including IMGN529/DEBIO 1562, including risks relating related to clinical studies, their timing and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the six-month period ended December 31, 2016 and other reports filed with the Securities and Exchange Commission.
Debiopharm International SA | Date: 2017-04-05
A device for separating and concentrating target particles or molecules from a fibrinogen containing sample of liquid comprises a container (1) for collecting the sample and a closure (2). The container (1) comprises a first end and a second end and at least one interior wall defining a reservoir portion (5) for receiving the sample. The reservoir portion (5) comprises at least one anchor element (4) to locally catch a polymerized fibrin pellet formed upon the addition of the sample into the container. The separation and concentration process is operated by trapping the target particles or molecules into the so-formed polymerized fibrin pellet that are captured on the anchor element (4).
Debiopharm International SA | Date: 2017-02-08
The present invention relates to fusion polypeptides comprising an FGFR2 polypeptide and to cDNAs encoding such fusion polypeptides. The invention also encompasses methods of diagnosing the presence of the fusion polypeptides or of a gene or RNA sequence coding therefore in a sample from a subject as well as methods of treatment of a tumor instructed by the latter diagnosis.
Debiopharm International Sa and Novartis | Date: 2012-04-11
The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis C virus infection.
Debiopharm International SA | Date: 2014-11-06
In part, the present disclosure is directed to prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide compounds with significant solubility and bioavailability profiles.
Debiopharm International SA | Date: 2013-09-23
This invention relates to the discovery of novel forms of Compound 1, including solvates, hydrates, and other crystalline forms. These novel forms of Compound 1 may impart advantages in pharmaceutical formulations incorporating them, including improved stability and bioavailability.
Debiopharm International S.A. | Date: 2016-09-14
A sample collection device for separating target molecules or particles from a sample comprising: (i) an identification code; (ii) a container for containing the said sample; and (iii) a fibrinogen-containing sample in the container, the device being operable to form a fibrin clot that traps in a separable manner the said target molecules or particles upon the exposure of the said sample to thrombin or a thrombin-like enzyme within the said device, wherein the concentration of fibrinogen within the said sample is between 10 to 100 mg/ml.
Debiopharm International SA | Date: 2015-03-18
The present application relates to antibacterial compounds (Fab1 inhibitors) of formula (I)A is a monocyclic ring of 4-7 atoms containing 0-2 heteroatoms, a bicyclic ring of 8-12 atoms containing 0-4 heteroatoms, or a tricyclic ring of 8-12 atoms containing 0-6 heteroatoms, wherein the rings are independently aliphatic, aromatic, heteroaryl or heterocyclic in nature, the heteroatoms are selected from N, S, or O, and the rings are optionally substituted with one or more substituents selected from the group consisting of C_(1-4)alkyl, OR, CN, OCF_(3), F, Cl, Br, and I; wherein R is H, alkyl, aralkyl, or heteroaralkyl;R isR_(4) is H, alkyl, aryl, hydroxy substituted alkyl, or -C(O)ONa;R_(5) is H, alkyl, or aryl;R_(6) is H, alkyl, or aryl; andL_(1) is O or H_(2);or a pharmaceutically acceptable salt thereof.